Abstract | INTRODUCTION: AREAS COVERED: EXPERT OPINION:
Agomelatine is a multi-modal agent with novel mechanisms of action, having sound evidence supporting its overall statistical efficacy and adequate tolerability profile for MDD treatment. However, the clinical significance of agomelatine has been contested, calling for additional studies in evaluation of its effect size. Of further concern are reported transient elevations in transaminases and severe but rare liver reactions.
|
Authors | Sarah E MacIsaac, André F Carvalho, Danielle S Cha, Rodrigo B Mansur, Roger S McIntyre |
Journal | Expert opinion on pharmacotherapy
(Expert Opin Pharmacother)
Vol. 15
Issue 2
Pg. 259-74
(Feb 2014)
ISSN: 1744-7666 [Electronic] England |
PMID | 24328686
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Acetamides
- Antidepressive Agents
- Receptor, Melatonin, MT1
- Receptor, Melatonin, MT2
- Serotonin 5-HT2 Receptor Antagonists
- agomelatine
|
Topics |
- Acetamides
(adverse effects, pharmacology, therapeutic use)
- Animals
- Antidepressive Agents
(adverse effects, pharmacology, therapeutic use)
- Circadian Rhythm
(drug effects)
- Depressive Disorder, Major
(drug therapy, physiopathology)
- Disease Models, Animal
- Humans
- Neurogenesis
(drug effects)
- Receptor, Melatonin, MT1
(agonists)
- Receptor, Melatonin, MT2
(agonists)
- Serotonin 5-HT2 Receptor Antagonists
(adverse effects, pharmacology, therapeutic use)
|